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661Abstracts
Rosuvastatin therapY I (MERCURY I) trial in which
3140 adults with, or at risk of, coronary heart disease ini-
tially received a ﬁxed daily dose of RSV 10mg, ATV 
10 or 20mg, PRA 40mg or SIM 20mg. After 8 weeks’
treatment, patients were randomised to remain on treat-
ment or to switch treatments as follows: from ATV 
10mg, SIM 20mg, PRA 40mg to RSV 10mg or from
ATV 20mg to RSV 10 or 20mg for a further 8 weeks. In
a decision-analysis model, it was assumed that patients
not achieving goal on an alternative statin after 8 weeks
would be switched to RSV. Costs for drug acquisition,
primary care physician visits, nurse visits and laboratory
tests were included where appropriate. Cost-effectiveness
was expressed as the cost per patient treated to LDL-C
goal over a 16-week period. RESULTS: Initiating and
maintaining patients on RSV was more cost-effective than
either 1) initiating and maintaining on another statin; 
or 2) switching from another statin to RSV 10mg. Com-
pared with continuing on ATV, PRA or SIM, switching
to RSV would treat more patients to goal at an incre-
mental cost of €17–117 per extra patient treated to goal.
CONCLUSIONS: Initiating and maintaining patients on
RSV were more cost-effective than switching from the
other statins to RSV. For patients intially receiving other
statins, switching to RSV treated more patients to goal at
relatively little additional total cost while drug costs were
equivalent or lower.
PCV47
A COST-EFFECTIVENESS ANALYSIS OF TAXUSTM
DRUG-ELUTING STENT IN THE UK
Wenk-Lang A1, Knight C2
1Boston Scientiﬁc International, La Garenne Colombes,
France, France; 2Heron Evidence Development Ltd,
Letchworth, United Kingdom
Coronary stents (metal mesh tube) are routinely used with
coronary angioplasty for the treatment of ischaemic heart
disease. As many as 25% of patients need reinterventions
post conventional coronary stenting due to re-narrowing
of the treated artery. OBJECTIVE: The objective is to
assess the total 6-month cost and the incremental cost-
utility of the TAXUSTM stent (TAXUS), a paclitaxel-
eluting coronary stent system, compared to conventional
stents (CS). METHOD: A decision analytical model was
developed to assess the 6-month cost and the incremen-
tal cost-utility of TAXUS compared to CS. The study
takes a UK NHS perspective. Clinical event rates for the
TAXUS and CS were taken from TAXUS II clinical trial.
Utility values were sourced from the literature. Unit cost
data were based on UK published sources. RESULTS:
Expected costs at 6 months were £4154 for CS and £4386
for TAXUS in the treated population. Compared to CS
TAXUS was cost saving in diabetic patients (CS £4546
vs. TAXUS £4152), cost neutral in small vessels (CS
£4301 vs TAXUS £4342) and slightly cost additive in
long lesions (CS £4306 vs TAXUS £4425). Most of the
initial increase in procedure cost is offset due to savings
in fewer repeat procedures. The incremental cost-utility
of TAXUS compared to CS ranged from £32,381/ QALY
in the total population to £4,500/ QALY in patients with
small vessels and to £13,500/ QALY in patients with long
lesions. In diabetic patients TAXUS was the dominant
strategy. CONCLUSIONS: Most of the initial increase in
procedural costs with TAXUS is offset due to savings in
repeat procedures. In some high-risk patient groups such
as diabetics and those with small vessels TAXUS is cost
saving or cost neutral. In all patient groups, TAXUS is a
cost-effective new treatment modality for patients with
coronary artery disease.
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OBJECTIVES: The use of early coronary catheterization
and revascularization in unstable coronary artery disease
(UCAD) varies, which could have important conse-
quences for patients as well as long-term costs. The 
objective of this study was to estimate the long-term 
cost-effectiveness and cost-utility ratios of this strategy.
METHODS: We analysed data in the open randomized,
clinical FRISC II invasive trial, which consisted of total
2457 patients, with signs and symptoms of UCAD. We
prospectively recorded the patients’ use of health services
as well as productivity losses. Health states scores were
obtained within the trial ﬁve times during the 2-years
follow-up. Results were analysed in both a societal and 
a health care provider perspective. The uncertainty was
handled using the net-beneﬁt approach. RESULTS: There
was a signiﬁcant 1.74% absolute reduction in mortality
in the invasive compared to the non-invasive group at
two-years follow-up. The difference in mean total cost
was SEK 11,386 $1,467). This difference was not signif-
icant. The estimated cost per quality adjusted life year
(QALY) gained for the invasive strategy, based on within
trial results and projected life expectancy, was SEK
22,873 ($2,948). The estimated cost per life year gained
was SEK 57,651 ($7,429). If costs of added life years were
included the cost per quality adjusted life year was SEK
78,077 ($10,061). CONCLUSIONS: Invasive strategy in
patients with unstable angina or non-ST-segment eleva-
tion myocardial infarction, was in the long-term per-
spective shown to be cost-effective. The results were
consistent in all subgroups.
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